JPRN-jRCT2080221795UnknownPhase 3
Dose-finding study of K-877 in combination with pitavastatin
Conditions
Trial Snapshot
- Phase
- Phase 3
- Sponsor
- Kowa Co., Ltd.
- Enrollment
- 168
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 75age old (—)
- Sex
- All
Inclusion Criteria
- •Dyslipidemia with high TG and high non-HDL-C
Exclusion Criteria
- •The subjects whom administration of pitavastatin are contraindicated for
- •The subjects who need to be taken any other anti lipidemic agent
Investigators
Similar Trials
Unknown
Phase 2
A phase 2 dose exploratory study of K-877DyslipidemiaJPRN-jRCT2080221294Kowa Co., Ltd.192
Active, not recruiting
Not Applicable
A dose-finding study of PTK787/ZK 222584 in combination with weekly vinorelbine and trastuzumab as treatment of patients with metastatic breast cancer overexpressing HER-2/neu pre-treated withy at least one line of chemotherapy. - NDMedDRA version: 6.1Level: SOCClassification code 10038604EUCTR2005-005669-12-ITAZIENDA OSPEDALIERA S. FILIPPO NERI18
Unknown
Phase 1
Clinical pharmacology study of K-877DyslipidemiaJPRN-jRCT2080222359Kowa Co., Ltd.32
Unknown
Phase 1
clinical pharmacology study of K-877DyslipidemiaJPRN-jRCT2080222360Kowa Co., Ltd.24
Completed
Phase 1
Pharmacokinetic study of K-877 in patients with Primary biliary cholangitisPrimary biliary cholangitisJPRN-jRCT2080223672Kowa Co., Ltd.8